For how we live.
A Cochrane review of 39 trials found a steroid injection lowered heel pain by about 6 points on a 100-point scale in the first month, and made no difference by six months. Most cases settle anyway.
A 503-patient trial found surgery no better than physiotherapy plus a steroid injection for frozen shoulder. A meta-analysis of 65 studies pointed to early intra-articular steroid as the one clear winner.
Patients in remission who stayed on the JAK inhibitor through a second year flared far less than those switched to placebo — 7.4% versus 59.5% — in an extension of the SELECT-GCA trial.
In the phase 3 GCAptAIN trial the interleukin-17A blocker did not significantly beat placebo for sustained remission at one year, leaving the IL-6 inhibitor tocilizumab as the proven steroid-sparing option.
Relacorilant kept blood pressure under control when patients who had responded were kept on it rather than switched to placebo. The pivotal trial randomised just 62 people.
Ten years of national anti-doping reports show NSAID declarations flat at about 45%, a significant shift away from COX-2 selective drugs, and glucocorticoids making up around 13% of all prohibited-substance findings.